EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Severe invasive pneumococcal disease beyond current vaccination recommendations: implications for higher-valency vaccines

Niccolò Ramponi, Beatrice Barda, Giuseppe Barilaro, Martine Gallacchi Bouvier, Linda Mueller, Alex Giannini, Zain Ahmed Raza, Giorgio Merlani, Enos Bernasconi, Marco Bongiovanni iD

European Journal of Clinical Microbiology & Infectious Diseases · 2026-11 · 45 (11) · 3419-3426

DOI: 10.1007/s10096-026-05602-5 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Clinical Microbiology & Infectious Diseases, online erschienen am 04.08.2026. Verfasst von Niccolò Ramponi und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infectious Diseases, Ente Ospedaliero Cantonale, Lugano, Switzerland. Hauptthemen laut MEDLINE: Pneumococcal Vaccines, Pneumococcal Infections, Streptococcus pneumoniae. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Università della Svizzera italiana.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

To describe the epidemiology, clinical characteristics, and serotype distribution of invasive pneumococcal disease (IPD) in adults in Southern Switzerland, and to evaluate the theoretical coverage of higher-valency pneumococcal conjugate vaccines, with particular focus on patients without current vaccination indications.

Methods

This retrospective study included all adults with microbiologically confirmed IPD admitted to four hospitals in Southern Switzerland between January 2019 and December 2024. Clinical data, serotypes, and vaccination status were collected. Theoretical vaccine coverage was calculated for PCV13, PCV15, PCV20, and PCV21. Multivariable logistic regression identified predictors of intensive care unit (ICU) admission and mortality.

Results

Among 210 patients (mean age 69.3 years), 79 (37.6%) were admitted to the ICU and 18 (8.6%) died. Charlson Comorbidity Index was the only independent predictor of both ICU admission (OR 1.25, 95% CI 1.02–1.57) and mortality (OR 2.37, 95% CI 1.54–3.64). Serotype 8 was the most frequent isolate (21.0%), followed by serotypes 3 (13.3%) and 4 (9.5%). Only 9.9% of patients had received prior pneumococcal vaccination. Fifty-six patients (26.7%) were aged < 65 years without comorbidities and had no vaccination indication; 44.6% of these were admitted to the ICU. Serotype 8 accounted for 30.4% of infections in this subgroup. PCV13 and PCV15 would have covered 28.6% and 33.9% of cases in non-eligible adults, whereas PCV20 and PCV21 would have covered 67.9% and 73.2%, respectively.

Conclusions

More than one-quarter of adult IPD occurred in individuals without current vaccination indications, with high rates of severe disease. Higher-valency conjugate vaccines could substantially expand serotype coverage in this population, supporting reconsideration of age-based vaccination strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pneumococcal VaccinesPneumococcal InfectionsStreptococcus pneumoniaeHumansAgedFemaleRetrospective StudiesSwitzerlandMaleSerogroupMiddle AgedAged, 80 and overVaccinationVaccines, ConjugateIntensive Care UnitsAdultVaccination Coverage

Stichwörter der Autor:innen

Streptococcus pneumoniaeAdult immunizationInvasive pneumococcal diseasePneumococcal conjugate vaccineSerotype replacementVaccination strategies

Substanzen

Pneumococcal VaccinesVaccines, Conjugate

Autor:innen und Institutionen

  • Division of Infectious Diseases, Ente Ospedaliero Cantonale, Lugano, Switzerland.
  • Department of Internal Medicine, Sant'Eugenio Hospital, Rome, Italy.
  • Institute of Integrated Diagnostics of Southern Switzerland IDISI, Ente Ospedaliero Cantonale (EOC), Bellinzona, Switzerland.
  • Cantonal Service for Public Health, Bellinzona, Switzerland.
  • Department of Biomedical Sciences, University of Southern Switzerland, Lugano, Switzerland.
  • Division of Infectious Diseases, Ente Ospedaliero Cantonale, Lugano, Switzerland. Marco.Bongiovanni@eoc.ch.

ORCID-Profile: Marco Bongiovanni

Förderung

  • Università della Svizzera italiana

Zitieren

APA

Ramponi, N., Barda, B., Barilaro, G., Gallacchi Bouvier, M., Mueller, L., Giannini, A., Raza, Z. A., Merlani, G., Bernasconi, E., & Bongiovanni, M. (2026). Severe invasive pneumococcal disease beyond current vaccination recommendations: implications for higher-valency vaccines. European Journal of Clinical Microbiology & Infectious Diseases, 45(11), 3419-3426. https://doi.org/10.1007/s10096-026-05602-5

Vancouver

Ramponi N, Barda B, Barilaro G, Gallacchi Bouvier M, Mueller L, Giannini A, et al. Severe invasive pneumococcal disease beyond current vaccination recommendations: implications for higher-valency vaccines. European Journal of Clinical Microbiology & Infectious Diseases. 2026;45(11):3419-3426. doi:10.1007/s10096-026-05602-5

BibTeX
@article{Ramponi2026,
  author = {Ramponi, Niccolò and Barda, Beatrice and Barilaro, Giuseppe and Gallacchi Bouvier, Martine and Mueller, Linda and Giannini, Alex and Raza, Zain Ahmed and Merlani, Giorgio and Bernasconi, Enos and Bongiovanni, Marco},
  title = {Severe invasive pneumococcal disease beyond current vaccination recommendations: implications for higher-valency vaccines},
  journal = {European Journal of Clinical Microbiology & Infectious Diseases},
  year = {2026},
  volume = {45},
  number = {11},
  pages = {3419--3426},
  doi = {10.1007/s10096-026-05602-5}
}
Kostenlos starten →